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Abstract 
The discovery of human induced pluripotent stem cells (hiPSCs) opened new avenues for 
research and potential clinical applications for tissue regeneration and engineering. In particular, 
hiPSCs may offer a long sought solution for obtaining large numbers of autologous cells 
sufficient for tissue engineering. For vascular tissue engineering, several methods of generating 
endothelial cells or perivascular cells from hiPSCs in vitro have been reported. We review the 
current developments in the generation of vascular progenitor cells from hiPSCs and their 
functional capacity in vivo, and discuss the opportunities and challenges ahead for clinical 
translation and modeling vascular diseases using hiPSC-derived vascular cells with a focus on 
diabetes. 
 
One sentence summary:  
Successful generation of hiPSC-derived vascular cells in vitro and functional blood vessels 
in vivo offers a hope for clinical translation, yet important hurdles remain. 
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Introduction 
Two types of cells are required to form a stable blood vessel: endothelial cells (ECs) and the 
perivascular cells (PVCs: pericytes or vascular smooth muscle cells)1-6. Stem cells have the 
potential to provide a limitless supply of proliferative progenitor cells that could be differentiated 
into vascular cells in vivo to form a mature and durable network of blood vessels7,8. However, 
adult stem cells have only limited proliferative potential, diminished differentiation capacity and 
increased senescence9. Human induced pluripotent stem cells (hiPSCs) offer a promising 
alternative10-12. Indeed, retroviral transduction of only 4 transcription factors is able to 
‘reprogram’ terminally differentiated cells of adult origin into pluripotent – an embryonic stem 
cell-like – state. The hiPSCs can, in principle, provide a rich source of non-immunogenic 
allogeneic stem or progenitor cells, capable of differentiation and organization into functional 
tissue in a biologically relevant microenvironment. Additionally, the use of hiPSC derivatives in 
humans would be free of ethical issues that arise with another pluripotent cell source – the 
human embryonic stem cells (hESCs)13,14. 
 Creation of stable and functional blood vessels in vivo from hiPSCs has tremendous 
potential for repairing diseased state of vasculature, tissue engineering and organ transplantation. 
Another vital application of hiPSC-derived blood vessels is the ability to examine the 
mechanisms of and test novel strategies to correct various vascular pathologies “in a dish”– such 
as diabetic vascular complications and abnormal vascular development. However, the challenge 
for any of these applications remains the ability to derive adequate numbers of healthy progeny 
from hiPSC-derived vascular progenitor cells that can form functional vessels in vivo and thus, 
could be used for clinical translation or disease modeling. We will give a brief historical 
overview of vascular tissue engineering followed by the discussion about new developments in 
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the generation of vascular progenitor cells from hiPSCs, their functional capacity in vivo, and 
opportunities and challenges for clinical translation in vascular disease such as diabetes. 
Vascular tissue engineering: The pre-hiPSC era  
The formation of blood vessels occurs mainly by two processes: 1) angiogenesis  – the formation 
of new vessels from existing blood vessels, and 2) vasculogenesis – de novo blood vessel 
formation2,15,16. Vascular tissue engineering involves an intricately orchestrated series of cellular 
and molecular events engaging vascular progenitor cells and non-vascular cells in a specialized 
microenvironment2,3,17. The applications of vascular tissue engineering include generation of 
vascular grafts18, and revascularization in chronic limb ischemia19. Significant developments in 
vascular tissue engineering include exploration of different sources of vascular cells, biologically 
relevant animal models of disease, sophisticated techniques for in vivo visualization of 
engineered blood vessels, and mechanistic insights4,20-23.   
 The growth factors and signaling pathways in vascular cells that control vasculogenesis 
and angiogenesis include vascular endothelial growth factor (VEGF) family, basic fibroblast 
growth factor (b-FGF), platelet derived growth factor (PDGF)-BB, Hedgehog family, Notch, 
semaphorins, Tie-2 and angiopoietins2,24-29. The controlled release of angiogenic growth factors 
in combination of extracellular matrices, biochemical and mechanical cues favor generation of 
blood vessels. The sequential delivery of VEGF and PDGF within scaffolds facilitated the 
formation of mature, remodeled blood vessels that alleviated hind limb ischemia in 
immunodeficient mice30. Another approach consisted of implantation of ECs, either alone or 
with perivascular cells, within appropriate scaffolds. Bovine aortic ECs– when co-implanted 
with 10T½ mouse embryonic mesenchymal stem/progenitor cells – caused the migration of 
10T½ cells towards the ECs, and upon contact, led to mesenchymal mural phenotype of 10T½ 
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cells in vitro31. Elegant mechanistic work demonstrated that the PVC facilitated stability of blood 
vessels via cross talk with ECs, a process that seems to be mediated PDGF-B and transforming 
growth factor-β (TGF-β)31,32. However, the exact mechanisms that facilitate stabilization of 
blood vessels and integration in host circulation in vivo still remain elusive.  
 Using pre-cellularized matrices for vascular engineering, we have successfully generated 
durable vascular networks in vivo using human umbilical vein ECs (HUVECs) along with 10T½ 
cells33. Our laboratory also established techniques for utilizing chronic “transparent” windows in 
animal models that allow visualization of vessel formation in vivo using a non-invasive imaging 
technique – laser scanning multiphoton microscopy – to examine the function of tissue 
engineered blood vessels4,20-23,33-37. Using this approach, we demonstrated that microvascular 
networks formed by co-implanting HUVECs with 10T½ cells remained durable and functional 
for nearly one year33. Furthermore, using this approach we revealed the mechanism of 
anastomosis of engineered vessels to host vasculature in vivo. Interestingly, we found that 
implanted ECs wrap around nearby host vessels, and subsequently cause reorganization of 
basement membrane and PVCs that leads to displacement of the host endothelium – a process 
termed “wrapping and tapping”23.  
 In an attempt to make this approach more translatable, we have further developed 
approaches using peripheral blood endothelial progenitor cells (EPCs) instead of HUVECs. 
Adult peripheral blood EPCs-derived blood vessels regressed within 3 weeks, whereas umbilical 
cord blood EPCs formed a functional vasculature, which lasted for more than 4 months – 
indicating that “stemness” plays a key role. This could be attributed to a higher proliferative 
capacity of cord blood derived EPCs when compared to peripheral blood EPCs as demonstrated 
by a higher proliferative Ki-67 index. Furthermore, cord blood-derived EPCs were more resistant 
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to stress induced apoptosis as compared to peripheral blood-derived EPCs, indicating a greater 
survival advantage of cord blood EPCs20. Ingram et al have demonstrated that cord blood-
derived EPCs have a higher level of telomerase activity as compared to peripheral blood-derived 
EPCs38. We also replaced the murine 10T½ cells with bone marrow-derived human 
mesenchymal stem cells (hMSCs), while others have used adipose tissue derived stem 
cells4,20,21,23,35-37,39,40.  The MSCs could differentiate into PVCs with a pericyte-like phenotype 
that stabilized vessels in vivo34. Finally, derivation of vascular progenitor cells from hESCs35,41-51 
generated tremendous excitement as a limitless source of cells that might be used for vascular 
tissue engineering35,44-46,51,52. To this end, we created functional blood vessels in vivo in mice by 
co-implanting hESC-ECs with 10T½ cells. These vascular networks lasted for at least 150 
days35. Although hESCs remain the gold standard of pluripotency and our data on hESC-ECs 
provided a proof of the principle for the stem cell-derived tissue engineered blood vessels, the 
use of hESCs in the clinic remains controversial.  
 Despite the above-mentioned advances in vascular tissue engineering, important 
challenges remain. Cell therapy-using EPCs has not been successful in generating robust 
vascular networks53. Therapeutic strategies using pro-angiogenic cells for peripheral vascular 
disease54 and ischemic heart disease55 have led to only modest functional improvement. These 
challenges in the field of vascular tissue engineering have so far precluded successful application 
in the clinic. It is known that vascular cells that are exposed to a hypoxic environment are 
vulnerable to cell death in vivo56. Given the heterogeneity of ECs, functionally viable engineered 
blood vessels may need a full complement of or specific ECs to form blood vessels including 
capillaries, arteries and venules57. One-size may not fit all also for perivascular cells, which vary 
depending on anatomic location, for instance PVC coverage is very tight in the brain vessels but 
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scant in vessels in the skeletal muscle1. Besides engineering the cellular components, it is equally 
relevant to pay attention to the biological composition of the scaffold that forms the 
microenvironment for EC/PVC interaction and stability. Inherent EC dysfunction and senescence 
of vascular cells with advanced aging is also likely to be also important9,58,59. 
The human induced pluripotent stem cell (hiPSC) era  
After Yamanaka’s groundbreaking method of reprogramming adult human fibroblasts using 
retroviral transduction of Oct-4 (octamer-binding transcription factor-4 also known as POU5F1), 
Sox-2 (SRY-related high-mobility-group (HMG)-box protein-2), Klf-4 (Kruppel-like factor 4) 
and c-Myc (cellular homolog of the myelocytomatosis viral oncogene)11, numerous other non-
integrating approaches have been reported. These included viral60-63, transgene free64-67, and non-
viral, including mRNA68,69 and small molecules70-72. These potentially safer methods of 
reprogramming offer the hope of clinical translation of hiPSC- derivatives, particularly those that 
offer zero-footprint technology. The roadblock to clinical translation included poor 
reprogramming efficiencies and a lack of full mechanistic understanding of the barriers to 
reprogramming14. It has recently been demonstrated that totipotent mouse iPSCs generated in 
vivo were closer to embryonic stem cells than in vitro generated hiPSCs73. The selected 
inhibition of a single factor, MBD3 (epigenetic repressor) radically amplified the reversion 
efficiency of primed mouse pluripotent epiblast cells to ground state pluripotency. Furthermore, 
more than 98% of mouse embryonic fibroblasts were reprogrammed in a week’s time, when the 
traditional 4 Yamanaka factors were combined with the genetic depletion of MBD374. These 
reports have resulted in an enhanced understanding of reprogramming mechanisms in mice and 
hiPSCs. 
 An outstanding issue for the field is whether the cell of origin of hiPSC (source) or 
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efficiency of reprogramming greatly influences differentiation potential of hiPSC cells75. The 
“memory” of hiPSC cells (expression of genes reflecting origin of cells) may diminish over 
passages in culture.  Ohi et al. reported somatic memory of gene expression in all hiPSC lines 
examined that correlated with retention of the demethylated status of genes normally methylated 
in ESCs76. This gene expression profile was noted even in hiPSC cells that were derived using 
non-viral, non-integrating techniques. Of greater concern is that the genes expressed have been 
associated with cancer, and thus a careful examination of the genome and epigenome of hiPSC-
derived cell lines is warranted prior to the clinical translation. Interestingly, Ohi et al. found that 
hepatocyte-derived hiPSC cells did not show a greater tendency to generate endoderm when 
compared with fibroblast-derived hiPSC cells76. Kim et al. demonstrated that blood-derived 
hiPSCs were less efficient in differentiating into keratinocytes than hESC cells suggesting that 
blood derived hiPSC cells may not be efficient in skin regeneration77. More recently, a 
comparison in differentiation properties of genetically matched hiPSC clones from bone marrow 
and dermal fibroblasts from the same patient did not reveal any significant differences in global 
gene expression profiles78. 
 The above concerns notwithstanding, the first hiPSC-based clinical trial using retinal 
pigment epithelial cells recently opened79,80. Companies such as Advanced Cell Technology have 
approached the Food and Drug Administration (FDA) in the United States for testing platelets 
derived from hiPSCs on humans80. A proposed trial using genetically corrected keratinocytes to 
treat Epidermolysis Bullosa by Stanford researchers is currently under review by the FDA 
(http://www.cirm.ca.gov/our-progress/awards/ips-cell-based-treatment-dominant-dystrophic-
epidermolysis-bullosa). In July 2013, the first human clinical study using hiPSC derived retinal 
pigment epithelial cells was approved for injection into the eyes of six patients diagnosed with 
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age-related macular degeneration, a condition that leads to blindness. As of September 1st, 2014, 
this trial was underway. This was first study in which genetically matched skin cells from age-
related macular degeneration patients that have been reprogrammed to hiPSCs and differentiated 
to retinal cells were implanted back into the patients79-81. The expectation of such a study is that 
the hiPSC-retinal cells will prevent ongoing destruction of photoreceptors. However, this 
approach is unlikely to repair vision that has already been lost. If successful, the landscape for 
hiPSC-derivatives for human translation will widen, dramatically79. The "proof of concept" for 
retinal sheet transplantation therapy for advanced retinal degenerative diseases has recently been 
demonstrated in mice 82. 
 The hope for hiPSC-derived tissue in regenerative medicine has been replacement of 
tissues or organs that would otherwise require transplantation. (Stem Cell Research: Trends and 
perspectives on the evolving international landscape: ”http://www.elsevier.com/online-
tools/research-intelligence/research-initiatives/stem-cell-research”). Indeed, hiPSC-derived 
hepatocytes produced a functional vascularized liver in mice83. hiPSC-derived hepatocytes, 
HUVECs and MSCs were used to engineer the liver organoids. It appears that a combination of 
cell types, and their cross talk is required for generating a functioning organoid such as the liver 
that can recapitulate physiological function in vivo. Significantly, the HUVECs were able to 
form blood vessels in the liver organoids as co-implanted MSCs were likely PVCs and stabilized 
the nascent vasculature84. Cerebral organoids or mini-brains derived from hiPSCs were created 
in a dish, and grew to their maximum size in 2 months85. The lack of vasculature, oxygen and 
nutrients to the core of the cerebral organoids may have prevented further development and 
growth.  
Human induced pluripotent stem cells as sources of vascular endothelial cells  
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ECs have been derived from hiPSCs (hiPSC-ECs) from a variety of types of cells: including 
neonatal or adult skin fibroblasts39,86-104, umbilical cord blood102 and HUVECs105. Bone marrow 
derived CD34+ progenitor cells106,107, amniotic fluid-derived cells108, neonatal lung 
fibroblasts106, dental pulp-derived cells94,109, MSCs104,110,111 and lipoaspirates63 have also been 
converted to hiPSCs and subsequently differentiated into ECs. The diverse methods used to 
reprogram ECs from hiPSCs include lentiviral10,37,86,89,90,94,97,103,104,107,110,112-114,115 
retroviral39,43,88,89,91-96,98,100,105,108,60,85,102,106,110,116,117, plasmid37,106,107 modified RNA 
technology86,102,110, 2-D or 3-D culture conditions, different combinations of transcription factors 
and feeder vs. feeder-free conditions. Derivation of hiPSC-ECs has also utilized a variety of 
selection markers (CD34, CD31, CD144/VE-Cadherin, CD146, Tie-2, FLT1, KDR, vWF) using 
flow cytometry of magnetic bead sorting as well as the addition of cytokines or pharmacologic 
agents in the culture media (BMP-4, VEGF-A, bFGF, Activin A, SCF, Flt3, Flt3L, IL-3, IL-6 or 
a MEK inhibitor) to promote EC differentiation (Supplemental Tables S1 and S2).  
 Studies have found that the gene expression of hESC-ECs and hiPSC-ECs is largely 
similar75. A high level of concordance of gene expression was also noted between ECs derived 
from the same hiPSC line which was confirmed in multiple experiments and using different 
protocols for hiPSC-EC differentiation75. Other studies of hiPSC-ECs from different cell lines 
and using multiple differentiation protocols have reported variability between in vitro and in vivo 
functionality of hiPSC-EC networks37. Transient reprogramming techniques have also been 
shown to be sufficient to generate bona fide ECs112. 
A full complement of ECs can be derived from hiPSCs suggesting that hiPSC-ECs are 
functionally diverse and presumably similar to human ECs57,96,102. Rufaihah et al. have 
demonstrated that varying the exposure to soluble growth factors in differentiation protocols for 
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hiPSC leads to cell differentiation into arterial, venous or lymphatic ECs96. Culturing in high 
VEGF concentration media led to an arterial-EC phenotype, low VEGF levels promoted venous 
specification, and a combination of high VEGF-C and Angiopoietin-1 levels favored lymphatic 
differentiation. hiPSC-ECs formed the most robust capillary networks in vivo in subcutaneous 
Matrigel plugs implanted in Severe Combined Immunodeficiency Deficient (SCID) mice96. 
These results suggest that the hiPSC-arterial ECs may be beneficial for therapeutic angiogenesis 
in hind limb ischemia, whereas hiPSC-lymphatic ECs may be more advantageous for treatment 
of lymphedema. Indeed, immature EPCs show plasticity between arterial and venous 
phenotypes116. An arterial phenotype of ECs is believed to be induced by NOTCH signaling 
involving shear stress and facilitated by a high concentration of VEGF in media used for 
endothelial differentiation75. It has been suggested that identification of early vascular precursor 
markers such as KDR117 or CD87118 may provide clues into endothelial specification in 
development, and perhaps provide access to vasculogenic clones of hiPSC-ECs37. 
  
Human induced pluripotent stem cells as sources of mural/ perivascular cells  
A prerequisite for vascular tissue engineering using hiPSC-ECs to become a reality is the 
availability of mural / perivascular cells (PVCs) such as pericytes and vascular smooth muscle 
cells (vSMCs) for stabilization and maturation of hiPSC-derived engineered blood vessels. 
Ideally these PVCs would be derived from the same autologous hiPSCs to facilitate clinical 
translation.  
Pericytes share lineage derivation, morphological, tri-lineage differentiation into adipocytic, 
osteogenic and chondrogenic potential in vivo, and expression of common surface markers with 
MSCs1. Indeed MSCs or mesenchymal progenitor cells with a perivascular location in vivo are 
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termed pericytes or cells with pericyte-like morphology and function. Intermediate or transition 
states are also known to exist between the different mural cell types such as described in the 
derivation of functional vSMCs from hiPSCs via MSC intermediate cells119. 
Pericytes are considered the microvascular counterparts of vSMCs. The two mural cells are 
differentiated by morphology, and the expression of cytosolic and membrane bound markers1,6. 
For example, whereas pericytes are specifically perivascular in location and attached to the 
longitudinal axis of capillaries with finger-like extensions, vSMCs are positioned 
perpendicularly to the entire endothelial surface. 
hiPSC-derived MSCs have been generated using neonatal or adult skin fibroblasts104,119-132, 
human vascular smooth muscle133, neonatal lung fibroblasts99, bone marrow-derived CD34+ 
progenitor cells106,108,128, hair keratinocytes119,132 and brain134 using 
retroviral37,111,113,123,127,128,131,132,134-137, lentiviral37,104,114,119,120,124,125,127,133,138, plasmid99, 124,130 
modified RNA technology130, 2-D or 3-D culture conditions, and different combinations of 
transcription factors and feeder vs. feeder-free conditions (Supplemental Tables S1 and 
S2)122,128. The derivation of hiPSC-mural cells has utilized a variety of selection markers and 
addition of growth factors to culture conditions with varying efficiency. Flow cytometry for the 
following markers CD73, CD146, CD105, CD90, CD24, CD44, CD54, NG2, PDGF-β, HSP90, 
HLA-class I have been used to characterize hiPSC-derived MSCs. hiPSC- derived SMCs/vSMCs 
have been characterized using α-smooth muscle actin, calponin, SM22, TCF15, MYH11, 
ACTA2, CNN1, CSPG4. Additionally magnetic bead sorting and the addition of cytokines to 
culture media (BMP-4, DKK3, PD98059, Flt3, SCF, VEGF, IL-3, IL-6) have been employed to 
promote the differentiation  of hiPSC-derived mural cells (Supplemental Tables S1 and S2).  
 Several reports showed hiPSC to MSC derivation and successful inoculation of these 
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hiPSC-MSCs in rodent models of ischemia104,125,129. However, based on the findings from the 
human bone marrow-derived MSCs, it is unclear how these MSCs participate in the 
revascularization, as the therapeutic properties of MSCs may also result from secretion of 
paracrine factors in addition to direct support139,140. Fibroblasts derived from hiPSCs and hESCs 
also support angiogenesis via paracrine mechanisms77. Dar et al. demonstrated that 
CD105+CD90+CD73+CD31– multipotent clonogenic mesodermal progenitor cells arising 
spontaneously from embryoid bodies (EBs) – termed ‘multipotent clonogenic mesodermal 
precursors’ – were positive for pericytic markers CD146, NG2 and PDGFR-β but were negative 
for α-smooth muscle actin. The cultured ‘multipotent clonogenic mesodermal precursors’ formed 
cartilage, bone, fat, and skeletal muscle cells and showed vasculogenic potential in Matrigel 
plugs when co-implanted with hESC-ECs or HUVECs. The EB-derived PVCs promoted both 
vascular and muscle regeneration in mice132. Besides the implications for using both ECs and 
pericytic derivatives from hiPSCs in vascular tissue engineering, this work also demonstrated 
that the hiPSC-EB model of PVC derivation may shed light on these elusive and often neglected 
perivascular-supporting cell. Another key finding was the generation of vascularized liver buds 
formed by the co-implantation of hiPSC-derived hepatocytes with non-hiPSC (HUVECs and 
MSCs). The development of the vascular network within the liver organoids within 2 days was 
attributed to the subset of MSCs behaving like pericytes, surrounding the HUVECs and 
stabilizing blood vessels, as has been demonstrated in the past33,83.  
 Comparative studies suggest that hiPSC-derived SMCs are similar to the human SMC, 
sharing gene expression patterns, epigenetic modifications and in vitro functional properties. 
hiPSC-SMCs from human aortic vascular SMCs were re-differentiated back to SMCs, and were 
remarkably similar to the parenteral cells133. hiPSC-SMCs derived from three progenitor 
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subtypes (lateral plate mesoderm, paraxial mesoderm and neuroectoderm) suggest that organ 
specific SMCs exist and are an important resource to understand human vascular disease and 
development131. Quicker generation of hiPSC-perivascular cells has been enabled by using 
transient reprogramming techniques99. Furthermore the limited proliferative potential of human 
MSCs/SMCs seems to be offset by a step wise approach to generate functional hiPSC-SMCs 
through a highly proliferative MSC progenitor cell population119. Importantly, the hiPSC-SMCs 
can be directed to adopt either a synthetic or contractile phenotype128. 
Functional evaluation of hiPSC-derived vascular cells in vivo 
Although several methods could be used to generate hiPSC-ECs, only a few studies have 
performed functional evaluation of hiPSC-ECs in vivo, with a follow up typically not extending 
beyond one month. hiPSC-ECs have promoted neovascularization in vivo in murine models of 
hind limb ischemia91,92,94, myocardial infarction63, and retinal ischemia/reperfusion injury141,142. 
hiPSC-ECs have also been shown to reduce collagen deposition in a mouse induced scleroderma 
model95, and, in combination with hiPSCs derived SMCs, to enhance vascularization in a murine 
dermal wound model104. Remarkably, the functional response of hiPSC-ECs to proinflammatory 
stimuli has also been demonstrated in vivo. hiPSCs-ECs were able to respond to biomechanical 
cues thereby directing differentiation into cells of the circulatory system110. The hiPSC-ECs 
exhibited an activated phenotype in response to pro-inflammatory stimuli, and revealed 
anticoagulant properties. The ability to modulate hiPSC-ECs to develop athero-protective or 
athero-prone phenotypes is exciting and shows potential for drug screening to prevent plaques of 
atherosclerosis. 
Ideally, the hiPSC-engineered blood vessel precursors to be used in the clinic should be Human 
Leukocyte Antigen (HLA)-matched. This could be achieved by generating both the ECs and 
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PVCs from the same individual. Indeed, our group and another one have demonstrated this 
possibility using different approaches37,106. Kusuma et al. derived early vascular cells from 
hiPSCs that were capable of maturing into both ECs and PVCs, organizing into vascular 
networks in hyaluronic acid based hydrogels106. The latter were infused with growth factors and 
implanted into immunodeficient mice. By day 3, vascular networks were demonstrable within 
the hydrogel. The hydrogels degraded in two weeks as designed. Explants were examined for a 
maximum duration of 2 weeks. 
 Our recent work demonstrated the longeveity of healthy hiPSC-engineered blood vessels 
in forming stable blood vessels in vivo (for 280 days in cranial window model, and 30 days in 
dorsal chambers in SCID mice)37. The EPCs were derived from hiPSCs using a novel triple 
combination of selection markers: CD34, neuropilin-1 (NP-1) and KDR, and an efficient 2-D 
culture system for hiPSC-EPC expansion. Non-invasive longitudinal in vivo microscopy was 
used to measure parameters, such as, permeability to bovine serum albumin, red blood cell 
(RBC) velocity and flow and to confirm function of blood vessels in vivo (Figure 1, Videos 1 
and 2). The RBC velocities of engineered blood vessels were comparable to normal endogenous 
host vessels (1.36 ± 0.3 mm/s), and demonstrated a higher permeability as compared to 
endogenous vessels. For the first time it was also shown that durable hiPSC-derived blood 
vessels were formed from endothelial and mesenchymal precursor cell types that were isolated 
from the same hiPSC line.37 Recently, another report validated that when human pluripotent stem 
cells were differentiated to ECs, the VE-Cadherin positive cells that were CD31+CD34+CD14–
KDRhigh exhibited high angiogenic and clonogenic proliferation among ECs143. 
Clinical translation of hiPSC-derived vascular cells 
Worldwide, there are currently 4,857 clinical trials registered at clinicaltrials.gov that involve 
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stem cells, with more than half of these in the USA (Supplemental Figure S1). Of these, 420 
clinical trials use stem cells for the treatment of peripheral vascular disease, and 144 clinical 
trials utilize stem cells to treat diabetes. There are 21 clinical trials enlisted with 
Clinicaltrials.gov that have used or are using hESC-derived products, primarily for eye disorders 
such as macular degeneration. Of note, currently, there are 32 trials enlisted with 
clinicaltrials.gov involving hiPSCs, from predominantly the USA (n=24). [France (n=3), Israel 
(n=2), Spain (n=1), United Kingdom (n=1) and Slovenia (n=1).] These studies include 
characterization of hiPSC-derived cells from cardiovascular disease, neurological disease, retinal 
degenerative diseases and immunodeficiency disorders. 
Currently there are no clinical trials that have utilized hiPSC-derived products for alleviating 
vascular disease such as peripheral limb ischemia or coronary heart disease. Thus, hiPSC-derived 
vascular cells have not yet impacted vascular tissue engineering. However, there is an increasing 
body of literature describing basic research using hiPSC-derived ECs and PVCs (in vitro studies 
and in vivo functional studies in mice), summarized in (Supplemental Tables 2 and 3).	   
The potential applications of hiPSC-derived vascular cells are wide, and include engineering 
blood vessels in coronary heart disease, alleviating critical limb ischemia in peripheral artery 
disease and examining the basis of diabetic vascular disease such as peripheral ischemia and 
potentially retinopathy. Heart disease and stroke remain outstanding causes of cardiovascular 
disease burden in the US. Coronary heart disease accounted for 1 in 6 deaths in 2009. The total 
burden of cardiovascular disease and stroke accounted for US $312.6 billion. This is startling 
when one considers that in 2008, the total cost of all benign and malignant neoplasms together in 
the USA was estimated at US $228 billion144. In 2010, stroke was the fourth leading cause of 
death in the USA. Worldwide, stroke is the second common cause of death after heart disease, 
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and is responsible for one-tenth of all deaths145. Thus, the potential benefit from the proposed 
approach is enormous. 
 
Modeling vascular diseases using hiPSCs for diabetes 
 In 2011, more than 371 million people worldwide had diabetes, and more than 471 billion 
USD was spent on healthcare for diabetes. By 2030, 552 million are expected to have diabetes. 
0.7% of these will develop retinopathy and become blind 
(http://www.idf.org/diabetesatlas/5e/Update2012). India is second to China in global prevalence 
of Type 2 diabetics (T2D), followed by the USA. Of the 63 million Indians with diabetes, it is 
alarming to note that a third of T2D have microvascular complications at presentation. In 
developing countries such as India, T2D vascular complications commonly result in diabetic foot 
ulcers and non-traumatic limb amputations146. hiPSC–derived vascular progenitor cells that 
could assist with revascularization of ischemic tissue could save limbs (Figure 2). However, in 
these vascular diseases, host endothelium is often dysfunctional59,147,148 and it is possible that the 
hiPSC-derived cells from a diseased patient carry such memory. Conversely, the re-setting of the 
epigenetic landscape as a consequence of reprogramming may yield hiPSC-derived vascular 
progeny with differences from their parent cell, which has been demonstrated in mice149.  
 Diabetic hiPSCs have been derived mainly for the differentiation or proposed 
differentiation to pancreatic β cells67,150-154. From a developmental perspective, however, it is 
known that the endothelium is instructive in providing signals that determine morphogenesis and 
cell differentiation of the pancreas155.  The value of obtaining diabetic hiPSC derived vascular 
cells would be most robust in examining monogenic diabetes such as Type 1 Diabetes (T1D) or 
Maturity onset diabetes of the young (MODY) 156. We have been successful in isolating hiPSC-
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derived ECs and PVCs from Type 1 diabetes and MODY cases37. While the T1D-iPS engineered 
blood vessels were functional for 4 months, the MODY-iPS-ECs failed to form functional blood 
vessels in vivo, despite demonstrating bona fide endothelial tube forming potential in vitro in 
Matrigel37. Further studies are needed to confirm and build on these provocative findings. 
 T2D hiPSC lines from elderly patients are capable of generating insulin-producing beta 
cells152. In contrast, there is no published data to date demonstrating the derivation of vascular 
progenitor cells from diabetic hiPSCs. The derivation of T2D-hiPSC-ECs and T2D-hiPSC-
perivascular cells might reveal a robust phenotype, which, even in the absence of a well-defined 
genetic background, may lead to mechanistic insights into vascular dysfunction in T2D. It is 
reasonable to speculate that our method of evaluation of hiPSC-engineered blood vessels from 
healthy controls, T1D and MODY patients37 could be applied to investigate T2D-hiPSC 
vasculature. 
Modeling non-diabetes vascular diseases using hiPSCs  
hiPSC derived vascular cells have been investigated from rare vascular diseases with known 
genetic mutations (Supplemental Table S3). hiPSCs from the premature ageing disease, 
Hutchinson Gilford Progeria Syndrome were differentiated into 5 lineages: neural progenitor, 
endothelial, fibroblasts, vSMCs and MSCs135. The Hutchinson Gilford Progeria Syndrome-
hiPSC-vSMCs survival was reduced under hypoxia, and Hutchinson Gilford Progeria Syndrome 
-hiPSC-MSCs were unable to prevent necrosis in a murine hind limb ischemia model, as 
compared with healthy MSCs. Williams Beuren Syndrome patient-derived fibroblasts from 
individuals with pulmonary and aortic stenosis were successfully differentiated to SMCs. These 
hiPSC-SMCs recapitulated the disease phenotype in vitro by demonstrating high proliferation 
and immature phenotype with low expression of differentiated SMC markers. The Williams 
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Beuren Syndrome-hiPSC-SMC phenotype was rescued by using rapamycin, a drug that inhibits 
smooth muscle proliferation. This result supports the testing of rapamycin in treatment of 
Williams Beuren Syndrome, and is an ideal example of the use of disease modeling with hiPSCs 
potentiating drug discovery or treatment modalities in the clinic. Supravalvular aortic stenosis–
hiPSC-SMCs similarly displayed an abnormal SMC phenotype that was rescued by the addition 
of exogenous trophoelastin or expression of the Ras homolog family member A (Rho A)114. 
hiPSCs differentiated into cardiomyocytes  from patients with LEOPARD syndrome 
demonstrated altered expression of various hypertrophy related genes and higher expression of 
TGF-β136. hiPSC-derived ECs from patients with Moyamoya disease, an idiopathic 
cerebrovascular disease that causes stroke in adults and children worldwide demonstrated 
impaired angiogenic ability, linked to the down regulation of the securin protein137.  
 Besides using hiPSCs to model vascular disease, hiPSC-ECs have been useful in 
generating an in vitro blood brain barrier (BBB) model86. The BBB is composed of specialized 
ECs known as brain microvascular ECs, PVCs and astrocytes. The inaccessibility of these 
cellular types from humans has resulted in studies of the BBB from rodents, cows or pigs. A 
robust BBB of human origin was created for the first time by the use of hiPSC derivatives. When 
hiPSCs were co-differentiated into neural cell and EC lineage, these hPSC-ECs acquired BBB 
properties such as expression of tight junction proteins, glucose transporter, and P-glycoprotein. 
These hPSC-ECs demonstrate extremely high trans-endothelial electrical resistance, low 
molecular permeability and polarized transporter activity in response to astrocytes co-culture. 
This work is exciting as it offers a meaningful platform to examine developmental aspects of 
BBB formation and more clinically relevant issues such as opportunities to promote BBB repair 
after stroke or restrain the recruitment of blood vessels by aggressive brain tumors. The in vitro 
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BBB model may also permit assessment of delivery of drugs. 
Conclusions and challenges in clinical translation of hiPSC-based engineered blood vessels 
Only 7 years have passed since Shinya Yamanaka demonstrated in a landmark study that it was 
possible to reprogram adult somatic cells back to an embryonic stem cell-like state. This 
discovery led to the hope of hiPSC-derived cells could be used in the clinic to treat a myriad of 
diseases81,157,158. However, as discussed next, many challenges remain, especially in engineering 
3-D tissues using hiPSCs. 
 Providing a vascular supply to newly generated tissue remains one of the most 
challenging barriers in building solid organs. Current situations of organ transplantation in the 
USA is dire: One patient is listed for transplant every 11 minutes, and 130 join this list every 
day. While 75 patients receive a transplant every day, 19 die due to non-availability of organs 
(http://www.thenationalnetworkoforgandonors.org/statistics.html). hiPSC derived vascular cells 
have broad application for regenerative medicine as blood vessels are essential for any functional 
organs as recently shown in the generation of functional liver in mice with co-implantation of 
hepatocytes, MSCs and vascular ECs83. The expectation is that genetically matched organs 
created will reduce the need for organ transplants in the future. But first we need to deal with 
such challenges as the variability of hiPSC lines and the long-term safety issues involved in the 
use of these cells, which are being addressed by researchers around the world. Animal models 
using hiPSC-derived retinal pigment epithelial cells showed negligible tumorigenic potential159. 
However, this issue remains important for current and future hiPSC clinical trial testing. We also 
need better ways of engineering organ-specific ECs. ECs are heterogeneous in both cellular 
content (arterial, venular or lymphatic) and function depending on anatomical location 
(fenestrated vs. non-fenestrated)57. Therefore engineering specific type of ECs or organ specific 
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ECs is biologically relevant and important for clinical application.  
 There are several outstanding issues that need to be addressed before hiPSC derived 
vascular progenitor cells find application in the clinic. Finding the appropriate vasculogenic 
clones and understanding the molecular mechanisms that confer vasculogenic potential are 
clearly more important than scaling up large number of hiPSC-vascular progeny. For example, 
we have shown that the selection of triple positive CD34+KDR+NP1+ cells provides highly 
vasculogenic cells, which form functional blood vessels in vivo when co-implanted with 
perivascular cells (Figure 1)37. We should also consider variability of hiPSC lines such as the 
cell of origin and reprogramming techniques. These factors will influence the success of hiPSC-
vascular derivatives in vascular regenerative medicine. Would the timing of vascular insult be 
critical in vascular therapy using hiPSC-derived vascular cells – similar to spinal cord injury 
where immediate cell therapy is necessary in order to elicit a response? When translating mice to 
human data, one can imagine efforts to scale up hiPSC-derived vascular cells may require 
bioreactors, facilities for clinical grade production, biocompatible scaffolds and release devices 
to track the immune response in vivo.  Another issue is the ability to obtain homogenous 
populations of cells derived from hiPSCs. Cost-effective therapy using hiPSC-derivatives 
remains a critical issue as manufacturing costs can be often prohibitive. The possibility that 
hiPSC derivatives might ‘drift’ to an immature or cancerous phenotype in vivo also remains a 
cause for concern81,159. Recent reports of tumors detected post treatment with stem cells 
reinforces the need for vigilant and prolonged follow-up160. 
 Above all, in the rush to produce safe and biologically relevant hiPSC-derived vascular 
progeny, the dire reality is that host endothelium is often dysfunctional in vascular disease and it 
is possible the hiPSC-derived cells carry such memory. The mechanistic understanding of 
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healthy EC generation would help to overcome this problem. As of today, the only clinical trial 
in progress uses retinal pigment epithelium to treat age-related macular degeneration. Other 
proposed clinical trials involving hiPSC derivatives include platelets, genetically corrected 
keratinocytes to treat epidermolysis bullosa. Other possible trials using hiPSCs include 
oligodendrocyte precursor cells, dopaminergic neurons, retinal ganglion cells, keratinocyte and 
hematopoietic grafts80,81. The hope is that hiPSC-derived vascular progenitor cells too will find 
place in clinical trials to alleviate vascular insufficiency.  Until this happens, hiPSC-derived 
vascular cells serve as an exceptional source to examine diseased cells in a dish (Figure 2). 
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 FIGURE LEGENDS: 
 
Figure 1: Multiphoton laser scanning microscopy image of engineered functional blood 
vessels in vivo in cranial window of SCID mice. hiPSC derived endothelial cells (green) co-
implanted with perivascular 10 T ½ cells (red). Red blood cells labeled with DiD far-red dye 
(blue). [Reproduced from Samuel, et al. Generation of functionally competent and durable 
engineered blood vessels from human induced pluripotent stem cells. Proc Natl Acad Sci U S A 
2013;110:12774-9.] 
 
Figure 2: Potential application of hiPSC-derived blood vessels: Disease models and 
regenerative medicine. 
 
 
Video 1: Multiphoton laser scanning image of iPS engineered blood vessels in vivo in Day 
12 cranial window of SCID mouse: Green e-GFP HS27-iPS Endothelial cells co-implanted 
with DsRed 10 T 1/2 cells. The endothelial cells have formed well developed conduits forming 
arborizing networks of varying caliber that are supported by the perivascular 10 T ½ cells and 
embedded in the collagen 1 gel (Second harmonic generation signal, blue). Custom made 
MPLSM using confocal laser- scanning microscope body (Olympus 300; Optical Analysis Corp) 
and a broadband femtosecond laser source (High performance MaiTai, Spectra-Physics, 
Mountain View, CA). 20X magnification, 0.95NA water immersion objective was used 
(Olympus XLUMPlanF1, 1-UB965, Optical Analysis). Two-µm thick optical sections were 
taken. Imaging field of view was 660 µm x 660 µm x 155 µm with a resolution of 1.3 µm x 1.3 
µm x 2 µm, 512 X 512 pixels with total of 228 slices taken. 
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Video 2: Multiphoton laser scanning image of iPS engineered blood vessels in vivo in Day 
12 cranial window of SCID mouse: Green e-GFP HS27-iPS Endothelial cells co-implanted 
with DsRed 10 T 1/2 cells. Far-red labeled 1,1-dioctadecyl-3,3,3,3-
tetramethylindodicarbocyanine perchlorate (DiD) –red blood cells (RBCs) from species-specific 
mice (SCID) have been transfused to the SCID mouse via tail vein injection (blue) demonstrate 
RBCs traversing perfused blood vessels including anastomoses of host blood vessels with iPS-
engineered vessel network. Custom made MPLSM using confocal laser- scanning microscope 
body (Olympus 300; Optical Analysis Corp) and a broadband femtosecond laser source (High 
performance MaiTai, Spectra-Physics, Mountain View, CA). 20X magnification, 0.95NA water 
immersion objective was used (Olympus XLUMPlanF1, 1-UB965, Optical Analysis).  
Two-µm thick optical sections were taken. Imaging field of view was 660 µm x 660 µm x 155 
µm with a resolution of 1.3 µm x 1.3 µm x 2 µm, 512 X 512 pixels with total of 228 slices taken. 
(Video 2 corresponds to same region of interest as video 1).  
Supplemental Table 1: Key developments in functional evaluation of Human induced pluripotent stem cell derived/ 
Directed differentiation to endothelial cells (hiPS-ECs) and perivascular cells in vivo 
Starting material/ cell lines Reprogramming method  3D/ 2D Reference 
Adult dermal fibroblasts Retroviral: OSKM 2D 1,2,3,4, 
Adult dermal fibroblasts,  Retroviral: OSKM 3D 5,6,7,1 
Adult dermal fibroblasts,  Retroviral: OSKM Not known 8 
Adult dermal fibroblasts, Lentiviral: OSKM+ Nanog 2D 1 
Adult dermal fibroblasts, Lentiviral: OSK+ Nanog and Lin28 3D 9 
Adult dermal fibroblasts, Lentiviral: OS+ Nanog and Lin28 3D 10 
Adult dermal fibroblasts Plasmids: OSKM 2D 1 
Human dental pulp Retroviral: OS and OSKM 3D 11 
Human lipoaspirate Genome editing with zinc finger nuclease technology 3D 12 
Human fetal/neonatal fibroblasts Retroviral: OSK 2D 13 
Human fetal/neonatal fibroblasts Plasmid: OSKM+ Lin28 2D 14 
Human fetal/neonatal fibroblasts Lentiviral: OS + Nanog and Lin 28 2D 15 
Human fetal/neonatal fibroblasts Lentiviral: OSKM+ Lin28 2D  
Human fetal/neonatal fibroblasts Lentiviral: OK 2D 16 
Human fetal/neonatal fibroblasts Lentiviral: OS+ Nanog, Lin 28 3D 17 
Bone marrow  Lentiviral: OS, Nanog, Lin 28 3D 17 
Bone marrow  Plasmid: OSKM + lin 28 2D 14 
Type 1 Diabetic  Retroviral: OSKM 2D 1 
Type 1 Diabetic Retroviral: OSK 2D 1 
Human foreskin fibroblasts and human hair 
keratinocytes Retroviral: OSKM 3D 18 
Human neonatal lung fibroblasts, Partially 
reprogrammed cells “PIPs” Plasmid: OSKM 2D 19 
Amniotic fluid Lentiviral: OS + Nanog and Lin28 2D 20 
Cord Blood Plasmid: OSKM 3D 14 
 
KEY: OSKM: OCT4, SOX2, KLF-4, C-MYC 
         3D refers to generation of three-dimensional embryoid body formation. 2D refers to two-dimensional     
         co-culture conditions. N/A: not available. 
 
Supplemental Table 2: Generation of Human induced pluripotent stem cell derived/ Directed differentiation to 
endothelial cells (hiPS-ECs) and perivascular cells. 
Starting material/ cell lines Reprogramming method / Feeders 
3D/ 
2D Salient features  Ref. 
Fetal and newborn foreskin 
fibroblasts and adult skin 
fibroblasts/  
1. Fetal and newborn 
foreskin fibroblasts: 
Lentiviral: OS + Nanog 
2. Adult skin fibroblasts: 
Lentiviral: OS + Nanog or 
OS + Nanog and Lin 28 
2D 
Differentiation pattern of hiPSC-ECs were similar to 
hESC 
 
21 
Adult dermal fibroblasts/ Retroviral: OSKM and OSK 2D 
First report of both hiPSC derived endothelial cells 
and mural cells with efficiency comparable to hESCs 22 
Fetal and newborn foreskin 
fibroblasts/ 
  
1. Lentiviral: OS+ Nanog 
and Lin 28 
2. Retroviral: OSKM  
3D 
More than 50% of hiPSC-ECs showed beta 
galactosidase staining. Less than 5% of hESC-ECs 
exhibited senescence with positive staining for beta-
galactosidase. 
23 
Adult dermal fibroblasts Retroviral: OSKM 2D 
Endothelial cells derived from hESCs and hiPSCs are 
comparable in function and proliferation and appear 
to be ‘younger’ than human aortic endothelial cells.  
24 
Fetal and newborn foreskin 
fibroblasts 
Lentiviral: OS+ Nanog and 
Lin 28 3D 
iPSCs  derived from human dermal fibroblasts are 
similar to hESCs in capacity to generate endothelial 
(and hematopoietic) cells in vitro 
25 
Human dental pulp cells and skin 
fibroblasts  Retroviral: OS and OSKM 3D 
Therapeutic response in hind limb ischemia and 
myocardial infarction mouse models within a week. 11 
Adult dermal fibroblasts Retroviral: OSKM 3D Arterial, venous and lymphatic endothelial cells generated ECs 6 
HUVECs  Retroviral: OSKM 2D 
Endo-iPS cells similar to hESCs in morphology, gene 
expression, differentiation capacity and methylation 
pattern.  
26 
Fetal foreskin fibroblasts 
 
Lentiviral: OS+ Nanog and 
Lin 28 3D 
In vitro subculture of hiPSC-ECs showed limited 
growth rate as compared with hES-ECs.  27 
Adult dermal fibroblasts Retroviral: OSKM 3D Overall findings suggest that early senescence is not an inevitable fate of hiPSC -ECs 28 
Human amniotic fluid  Retroviral; OSKM  2D 
Clonally expanded cardiovascular progenitor cells are 
capable of differentiating into cardiovascular, 
endothelial and smooth muscle lineage.  
29 
Dermal fibroblasts; neonatal and 
foreskin, and cord blood. 
I. Integrative approach: 
Cord blood: Retroviral: OS 
Keratinocytes: 
Retroviral:OSKM or OSK 
and miR302-367. 
II. Non –integrative 
approach: 6-factor 
combination Oct-4, Sox-2, 
Klf-4, non-transforming l-
myc (MYC1), Lin-28 and 
short hairpin RNA against 
p53 
 
Partial de-differentiation reprogramming strategy led 
to multipotential progenitor cells from CD34+ 
population, including endothelial and smooth muscle 
cells. Endothelial cells arterial, venous and lymphatic 
phenotype.  
30 
Neonatal foreskin fibroblasts, BJ1 
cell line 
 
Normal control (HFF) ,BMC1 
 
Human dermal fibroblasts 
 
Human MSC line, MSC-1 
 
Retroviral: OSKM 
 
 
Lentiviral: OSKM 
 
Modified –RNAs: OSKM 
 
Retroviral: OSKM+ 
hTERT, SV40 Large T ag 
3D 
ECs derived from hiPSCs were able to respond to 
biomechanical cues thereby directing differentiation 
into cells of the circulatory system. The hiPSC-ECs 
mounted an activated phenotype to pro-inflammatory 
stimuli, and revealed anticoagulant properties.  
31 
IMR90-TZ1  
 
 
Bone marrowBM CD34 derived 
iPS cell line (BC1) 
Lentiviral: OS+ Nanog and 
Lin28 
 
1 or 2 EBNA/OriP plasmids 
used. 
3D Inhibition of TGF-β1 after mesoderm induction boosts cells of endothelial and hematopoietic lineage. 32 
Fetal lung fibroblasts 
 
Bone marrow 
 
GFP transgenic hiPSC line from 
Human Cord blood derived 
endothelial cells 
Retroviral: OSK  
 
Plasmid: OSKM + lin 28.  
 
Lentiviral: OS+ Nanog and 
Lin 28 
2D 
 
By Day 3, ‘Early vascular cells’ derived from hiPSCs 
were capable of maturing into both endothelial cells 
and pericytes. 
 
 
14 
Human Bone marrow derived 
mesenchymal stem cells and skin 
fibroblasts  
Retroviral: OSKM 3D Differentiated hBMMSC-iPSCs contained ` 20% CD34+ progenitor cells  33 
Adherent cultures from 30 human 
samples, brain: cerebral cortical 
tissue and deep seated non-
traumatic malignant lesions 
Retrovirus mediated co-
expression of transcription 
factors: Sox2 and Mash1. 
Reprogrammed cells 
termed human pericyte 
derived induced neuronal 
cells (hPdiNs) 
2D 
Cultures from adult human cerebral cortex with 
pericytic phenotype were reprogrammed to neuronal 
cells using the two transcription factors Sox2 and 
Mash1.  
34 
Human foreskin fibroblast and 
human hair follicle MSC  
Lentiviral: OS +,Nanog, 
and Lin28 
Lentiviral: OSKM 
2D 
A stepwise approach was taken to generate functional 
SMC through an intermediate highly proliferative 
MSC progenitor cell population.  
35 
Adult human dermal fibroblasts 
from excess skin of patient 
undergoing plastic surgery 
Retroviral: OSKM 2D 
SMCs derived from three progenitor subtypes (lateral 
plate mesoderm, paraxial mesoderm and 
neuroectoderm) displayed contractile activity and 
surrounded vascular structures in vivo.  
36 
Neonatal foreskin fibroblasts BJ-
iPSC Retroviral: OSKM 3D 
TGF-β1 efficiently induced the differentiation of 
iPSC-NCSCs into SMC lineage. 37 
Human iPSC line, 
SES 2, 5, 8, 9 and 10.  
Lentiviral: OSK + Nanog 
and Lin28. 3D 
iPSCs from human aortic vascular smooth muscle 
(HASMC) were redifferentiated back to SMCs.  38 
Human fibroblasts mRNA reprogramming: OSK  2D 
iPSC-MSCs were functionally compatible with two 
3D scaffolds tested, forming typically calcified 
structures within the scaffolds.  
39 
Bone marrow Plasmid: OSKM 3D MSCs were genetically modified for BMP2 delivery.  8 
Adult fibroblasts Lentiviral: OS+ Nanog and Lin28 3D 
The small molecule    SB431542 (TGF-β inhibitor) 
was used as a single-step method to direct the 
mesengenic differentiation of hiPSCs.  
40 
Amniotic fluid cells  Lentiviral:OS+ Nanog and Lin 28 2D 
hiPS-MSCs inhibited Natural killer (NK) cell 
proliferation and cytolytic mechanisms.  
20, 
41 
Foreskin  Retroviral: OSKM N/A MSC-like cells were derived from  hiPSCs, in one step.  42 
Foreskin Lentiviral: OS+ Nanog and Lin28 2D 
Bone marrow MSCs (BM-MSCs) display diminished 
proliferative capacity with repeat passages. The 
authors postulated that differential expression of ion 
channels in IPS-MSCs re responsible for their higher 
proliferative capacity than BM-MScs. It was 
discovered that the hEAG1 channel played a crucial 
role in the proliferative capacity of human IPS-MSCs 
and to a lesser degree, in BM-MSCs. 
41 
 
KEY: OSKM: OCT4, SOX2, KLF-4, C-MYC 
         3D refers to generation of three-dimensional embryoid body formation. 2D refers to two-dimensional     
         co-culture conditions. N/A: not available. 
Supplemental Table 3: Modeling diseases using human induced pluripotent stem cell derived endothelial cells (hiPS-
ECs) / perivascular cells  
Starting material/ cell lines Reprogramming method 3D/ 2D Salient features  
Ref. 
Hutchinson Gilford Progeria 
Syndrome (HGPS): HGPS patient 
fibroblast cells from Coriell cell 
repositories 
Retroviral: 
OSKM 
 
3D 
HGPS-IPS cells differentiated into neural progenitor 
cells, endothelial cells, fibroblasts, VSMCs and 
MSCs.  
HSPG-iPS-MSCs were unable to prevent necrosis in a 
hind limb ischemia model, in comparison with 
healthy MSCs.  
43 
Fetal foreskin fibroblasts 
 
 
 
Human foreskin fibroblasts 
 
Lentiviral: OS+ Nanog and 
Lin28 
 
Episomal vectors: OSKM+ 
Nanog, Lin-28, SV40LT 
and hTERT . 
2D hIPS-ECs acquire BBB properties when co-cultured with neural cells.. 
44 
Williams Beuren syndrome 
(WBS) fibroblasts from patient 
with pulmonary and aortic 
stenosis was used. Human aortic 
vascular smooth muscle and 
HUVECs were controls. 
Retroviral: OSKM. 3D 
The WBS-iPS-SMCs recapitulated the disease 
phenotype in vitro. The abnormal WBS-iPS-SMC 
phenotype was rescued by up regulating the ELN 
signaling pathway, or by using rapamycin.  
45 
Vascular SMCs derived by 
explant outgrowth from excised 
epicardial coronary artery of 
Supravalvular aortic stenosis 
(SVAS) patient 
Lentiviral; hSTEMCAA 
polycistronic vector:OSKM  3D 
SVAS-iPS-SMCs produced reduced amounts of 
elastin, reduced actin polymerization, increased 
proliferation and increased migration as compared to 
wild type controls. The abnormality was rescued by 
the addition of exogenous trophoelastin or Rho A. 
46 
Adult dermal fibroblasts from 
patients with LEOPARD 
syndrome and human dermal 
fibroblasts  
Retroviral: OSKM 
3D, 
and 
2D 
Selection of CD166 provided a pure population of 
CMs (>90%). Techniques utilized isolated non-CMs 
also (ECs and SMCs). L2 iPS6-CM showed altered 
expression of various hypertrophy related genes and 
higher TGF-beta.  Hypertrophic cardiomyopathy is a 
major disease type in patients with LEOPARD 
syndrome. 
47 
Dermal fibroblasts from 3 patients 
with Moyamoya Disease (MMD); 
unaffected carrier, and two 
healthy controls taken 
Retroviral: OSKM 2D 
Angiogenic activities of iPS-ECs from MMD patients 
and carrier were lower than wild type cases, with 
down regulation of the gene Securin. 
48 
	  
 
KEY: OSKM: OCT4, SOX2, KLF-4, C-MYC 
         3D refers to generation of three-dimensional embryoid body formation. 2D refers to two-dimensional     
         co-culture conditions. N/A: not available. 
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